2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T713,The disease burden of human papillomavirus (HPV)-related cancers is substantial, irrespective of sex. Establishing evidence on the effectiveness of the 9-valent HPV vaccine for males may support the implementation of sex-neutral HPV vaccination strategies. To evaluate the incidence of HPV-related cancers between 9-valent HPV-vaccinated and unvaccinated males using a large-scale database. This multicenter retrospective cohort study utilized a global database. Participants included males aged 9 to 26 years who were either unvaccinated or received at least one 9-valent HPV vaccine between January 2016 and December 2024 with outcomes followed-up for up to 10 years. The primary composite outcomes were HPV-related cancers, including head and neck, esophageal, anal, and penile cancers. Hazard ratios (HRs) were estimated using propensity score matching. Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03). This study found a significant negative association of the 9-valent HPV vaccine with HPV-related cancers in adolescents and young adult males and contributes to the development of sex-neutral HPV vaccination.31:Tc68, Importance The disease burden of human papillomavirus (HPV)–related cancers is substantial, irrespective of sex. Establishing evidence on the effectiveness of the 9-valent HPV vaccine for males may support the implementation of sex-neutral HPV vaccination strategies. Objective To evaluate the incidence of HPV-related cancers between 9-valent HPV-vaccinated and unvaccinated males using a large-scale database. Design, Setting, and Participants This multicenter retrospective cohort study utilized a global database. Participants included males aged 9 to 26 years who were either unvaccinated or received at least one 9-valent HPV vaccine between January 2016 and December 2024 with outcomes followed-up for up to 10 years. Main Outcomes and Measures The primary composite outcomes were HPV-related cancers, including head and neck, esophageal, anal, and penile cancers. Hazard ratios (HRs) were estimated using propensity score matching. Results Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03). Conclusions and Relevance This study found a significant negative association of the 9-valent HPV vaccine with HPV-related cancers in adolescents and young adult males and contributes to the development of sex-neutral HPV vaccination. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Anal Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Anal Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Anal%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Anal Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Anal%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Anal Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Anal Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.20892/j.issn.2095-3941.2026.0129","pmid":"42557895","title":"Anogenital human papillomavirus infection patterns by anatomical site and sexual orientation in Chinese men: a national multi-center study","journal_title":"Cancer Biology & Medicine","journal_issn":"2095-3941","published_at":"2026-08-04T00:00:00.000Z","url":"https://doi.org/10.20892/j.issn.2095-3941.2026.0129","source_score":122,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-22T06:53:45.376Z","updated_at":"2026-08-22T06:53:45.376Z","tags":[{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"condition","value":"Anal Cancer","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"condition","value":"Human Papillomavirus Infection","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"condition","value":"Penile Cancer","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"generic","value":"nonavalent HPV vaccine","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"modality","value":"HPV Vaccine","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"sample_size","value":"n=9000","value_numeric":9000},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"study_design","value":"Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"warning","value":"MSM were a minority subgroup (n=1,200 vs. 7,800 HM), and their trial recruitment method may not reflect the broader MSM population in China.","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"warning","value":"The study detects 25 HPV genotypes via SureX assay — genotypes outside this panel are not captured, potentially underestimating true prevalence.","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"warning","value":"This is a baseline analysis from an ongoing vaccine trial; longitudinal efficacy and final trial data are not yet available.","value_numeric":null},{"paper_doi":"10.20892/j.issn.2095-3941.2026.0129","tag_type":"warning","value":"Three authors are employees or shareholders of Beijing Health Guard Biotechnology Inc., the trial funder, which may introduce conflict-of-interest bias in data interpretation.","value_numeric":null}],"summaries":{"what_studied":"Baseline anogenital HPV prevalence and genotype distribution were assessed across three anatomical sites (external genitalia, perineal–perianal area, anal canal) in 9,000 HIV-negative Chinese men aged 18–45 years (7,800 heterosexual men [HM] and 1,200 MSM) enrolled in a multicenter nonavalent HPV vaccine trial across 17 centers in China (2022–2023).","key_result":"Total anogenital HPV prevalence was 33.7% in HM and 60.9% in MSM (P < 0.05). In HM, prevalence was highest at external genitalia (26.1%); in MSM, it was highest at the anal canal (45.1%) and perineal–perianal area (42.4%). HPV-52 was the most prevalent HR-HPV type in both groups. MSM had markedly higher HPV-16 (12.8%) and HPV-6/11 (anal canal 6.9%/4.8%) prevalence; multi-HR-HPV anal canal co-infection was 12.5% in MSM. Concurrent infection across ≥2 sites affected 15.4% of HM vs. 41.4% of MSM.","limitations":"- Baseline cross-sectional data only; causality and temporal trends cannot be established.\n- Participants were enrolled in a vaccine trial, which may introduce selection bias and limit generalizability.\n- Individual-level data remain masked pending trial completion, limiting external validation.","practice_takeaway":"The high HPV burden in both HM and MSM — especially HPV-52, HPV-16, and HPV-6/11 in MSM anal sites — supports expanding HPV vaccination to include men, with particular priority for MSM. Clinicians should consider multi-site anogenital sampling in MSM, as anal canal and perineal–perianal infections are far more prevalent than external genital infections in this group."}},{"doi":"10.1136/sextrans-2026-056940","pmid":"42236158","title":"Anal HPV type prevalence in gay, bisexual and other men who have sex with men following an opportunistic HPV vaccination programme in Scotland: a repeated cross-sectional study","journal_title":"Sexually Transmitted Infections","journal_issn":"1368-4973","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1136/sextrans-2026-056940","source_score":5,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:22.745Z","updated_at":"2026-06-10T14:24:22.745Z","tags":[{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"condition","value":"Anal Cancer","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"condition","value":"Anal Human Papillomavirus Infection","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"modality","value":"HPV Vaccine","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"modality","value":"Quadrivalent Vaccine","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"study_design","value":"Repeated Cross-Sectional Study","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"warning","value":"The rise in non-vaccine high-risk HPV types may reflect surveillance bias, behavioural changes, or type replacement — the study design cannot differentiate these explanations.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"warning","value":"Total sample size (N) is not reported in the abstract or results excerpt; sample_size tag was omitted.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2026-056940","tag_type":"warning","value":"Vaccine brand name is not specified beyond 'quadrivalent'; no brand tag applied.","value_numeric":null}],"summaries":{"what_studied":"This repeated cross-sectional study evaluated the impact of Scotland's opportunistic quadrivalent HPV vaccination programme (launched July 2017) for GBMSM by monitoring changes in anal HPV type prevalence via rectal swabs collected at a city centre sexual health clinic at baseline and at three subsequent timepoints over 4 years.","key_result":"By 2021, prevalence of quadrivalent vaccine-targeted HPV types fell 23% vs. baseline (PR 0.77, 95% CI 0.70–0.86, p<0.001); however, other high-risk HPV types rose 25% (PR 1.25, 95% CI 1.12–1.40, p<0.001), and overall anal HPV prevalence remained high across all years, peaking in 2019/2020.","limitations":"- Cross-sectional design prevents causal inference or tracking of individual vaccination status.\n- Single city centre clinic limits generalisability to GBMSM in other settings.\n- Cannot distinguish direct vaccine protection from indirect herd-immunity effects of the routine programme.","practice_takeaway":"HPV vaccination for GBMSM appears to reduce vaccine-targeted anal HPV types, supporting its role in anal cancer prevention. Clinicians should note the concurrent rise in non-vaccine high-risk HPV types, reinforcing the need for ongoing anal cancer screening alongside vaccination."}},{"doi":"10.1001/jamaoncol.2026.0496","pmid":"41954909","title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2026-04-09T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/","source_score":508,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-14","doi":"10.1001/jamaoncol.2026.0496","days":"30","issn":"2374-2437","rank":"3","field":"Clinical Medicine","score":"508","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1001/jamaoncol.2026.0496","title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males.","journal":"JAMA oncology","methods":"","results":"Before propensity score matching, 615 155 vaccinated males (mean [SD] age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean [SD] age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03).","abstract":"$30","keywords":[],"pubmed_id":"41954909","conclusions":"","publication_date":"2026-04-09T00:00:00"},"crossref":{"DOI":"10.1001/jamaoncol.2026.0496","URL":"https://doi.org/10.1001/jamaoncol.2026.0496","ISSN":["2374-2437"],"link":[{"URL":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2847524/jamaoncology_kitano_2026_oi_260011_1775077762.09379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males"],"author":[{"given":"Taito","family":"Kitano","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Clinical Research Center, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}]},{"given":"Sayaka","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Prefecture General Medical Center, Nara, Japan"},{"name":"Clinical Research Center, Nara Prefecture General Medical Center, Nara, Japan"}]}],"issued":{"date-parts":[[2026,4,9]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-04-09T15:00:28Z","timestamp":1775746828000,"date-parts":[[2026,4,9]]},"indexed":{"date-time":"2026-05-02T01:56:10Z","timestamp":1777686970850,"date-parts":[[2026,5,2]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2847524"}},"subtitle":[],"deposited":{"date-time":"2026-04-09T15:00:30Z","timestamp":1775746830000,"date-parts":[[2026,4,9]]},"issn-type":[{"type":"print","value":"2374-2437"}],"published":{"date-parts":[[2026,4,9]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1136/bmj-2022-070115","key":"coi260011r1","year":"2022","issue":null,"author":"Rahangdale","volume":"379","first-page":null,"unstructured":null,"article-title":"Human papillomavirus vaccination and cervical cancer risk.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(19)30488-7","key":"coi260011r2","year":"2020","issue":"2","author":"de Martel","volume":"8","first-page":"e180","unstructured":null,"article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdq454","key":"coi260011r3","year":"2010","issue":null,"author":"Syrjänen","volume":"21","first-page":"vii243","unstructured":null,"article-title":"The role of human papillomavirus infection in head and neck cancers.","journal-title":"Ann Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10552-017-0870-6","key":"coi260011r4","year":"2017","issue":"3","author":"McDonald","volume":"28","first-page":"203","unstructured":null,"article-title":"Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.","journal-title":"Cancer Causes Control","doi-asserted-by":"publisher"},{"DOI":"10.32481/djph.2019.05.005","key":"coi260011r5","year":"2019","issue":"2","author":"Savoy","volume":"5","first-page":"18","unstructured":null,"article-title":"Vaccination is the most effective strategy for HPV prevention.","journal-title":"Dela J Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.lanepe.2024.101178","key":"coi260011r6","year":"2025","issue":null,"author":"Wu","volume":"49","first-page":null,"unstructured":null,"article-title":"Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study.","journal-title":"Lancet Reg Health Eur","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.amjmed.2025.10.016","key":"coi260011r7","year":"2025","issue":"3","author":"Hung","volume":"139","first-page":"311","unstructured":null,"article-title":"HPV vaccination is associated with lower risk of cancers among females.","journal-title":"Am J Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD015364.pub2","key":"coi260011r8","year":"2025","issue":"11","author":"Bergman","volume":"11","first-page":null,"unstructured":null,"article-title":"Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD015363.pub2","key":"coi260011r9","year":"2025","issue":"11","author":"Henschke","volume":"11","first-page":null,"unstructured":null,"article-title":"Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.3389/fonc.2022.926555","key":"coi260011r10","year":"2022","issue":null,"author":"Guo","volume":"12","first-page":null,"unstructured":null,"article-title":"Trends in oropharyngeal cancer incidence among adult men and women in the United States from 2001 to 2018.","journal-title":"Front Oncol","doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers15051452","key":"coi260011r11","year":"2023","issue":"5","author":"Restivo","volume":"15","first-page":"1452","unstructured":null,"article-title":"Impact of preventive strategies on HPV-related diseases: ten-year data from the Italian Hospital Admission Registry.","journal-title":"Cancers (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1093/infdis/jiae345","key":"coi260011r12","year":"2024","issue":"5","author":"Alessandrini","volume":"230","first-page":"e1039","unstructured":null,"article-title":"Prevalence of oral human papillomavirus infection among urban gay, bisexual, and other men who have sex with men in Canada, 2017-2019.","journal-title":"J Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2025.103290","key":"coi260011r13","year":"2025","issue":null,"author":"Han","volume":"84","first-page":null,"unstructured":null,"article-title":"Global HPV vaccination programs and coverage rates: a systematic review.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.1017/S0950268817000747","key":"coi260011r14","year":"2017","issue":"10","author":"Signorelli","volume":"145","first-page":"1962","unstructured":null,"article-title":"Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.","journal-title":"Epidemiol Infect","doi-asserted-by":"publisher"},{"DOI":"10.12659/MSM.947173","key":"coi260011r15","year":"2025","issue":null,"author":"Miazga","volume":"31","first-page":null,"unstructured":null,"article-title":"Global guidelines and trends in HPV vaccination for cervical cancer prevention.","journal-title":"Med Sci Monit","doi-asserted-by":"publisher"},{"DOI":"10.3390/vaccines12010004","key":"coi260011r16","year":"2023","issue":"1","author":"Malvolti","volume":"12","first-page":"4","unstructured":null,"article-title":"The Global demand and supply balance of the human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer.","journal-title":"Vaccines (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2025.1516126","key":"coi260011r17","year":"2025","issue":null,"author":"Ludwig","volume":"16","first-page":null,"unstructured":null,"article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.","journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2023.2239085","key":"coi260011r18","year":"2023","issue":"2","author":"Ellingson","volume":"19","first-page":null,"unstructured":null,"article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1097/AOG.0000000000005056","key":"coi260011r19","year":"2023","issue":"2","author":"Boitano","volume":"141","first-page":"324","unstructured":null,"article-title":"An update on human papillomavirus vaccination in the United States.","journal-title":"Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.3390/v16050680","key":"coi260011r20","year":"2024","issue":"5","author":"Jensen","volume":"16","first-page":"680","unstructured":null,"article-title":"Human papillomavirus and associated cancers: a review.","journal-title":"Viruses","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.70198","key":"coi260011r21","year":"2025","issue":"9","author":"Stein","volume":"34","first-page":null,"unstructured":null,"article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/cts.70093","key":"coi260011r22","year":"2025","issue":"1","author":"Olaker","volume":"18","first-page":null,"unstructured":null,"article-title":"With big data comes big responsibility: strategies for utilizing aggregated, standardized, de-identified electronic health record data for research.","journal-title":"Clin Transl Sci","doi-asserted-by":"publisher"},{"DOI":"10.14740/wjon1104w","key":"coi260011r23","year":"2018","issue":"3","author":"Dhull","volume":"9","first-page":"80","unstructured":null,"article-title":"Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences.","journal-title":"World J Oncol","doi-asserted-by":"publisher"},{"DOI":"10.5493/wjem.v14.i3.98525","key":"coi260011r24","year":"2024","issue":"3","author":"English","volume":"14","first-page":"98525","unstructured":null,"article-title":"Anal carcinoma—exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.","journal-title":"World J Exp Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/codi.16324","key":"coi260011r25","year":"2023","issue":"1","author":"Brenne","volume":"25","first-page":"44","unstructured":null,"article-title":"Risk factors for right colon, left colon and rectal cancers differ between men and women: the population-based HUNT study in Norway.","journal-title":"Colorectal Dis","doi-asserted-by":"publisher"},{"DOI":"10.1097/MOU.0000000000000581","key":"coi260011r26","year":"2019","issue":"2","author":"Douglawi","volume":"29","first-page":"145","unstructured":null,"article-title":"Penile cancer epidemiology and risk factors: a contemporary review.","journal-title":"Curr Opin Urol","doi-asserted-by":"publisher"},{"DOI":"10.3390/vaccines11061083","key":"coi260011r27","year":"2023","issue":"6","author":"Rosado","volume":"11","first-page":"1083","unstructured":null,"article-title":"Impact of human papillomavirus vaccination on male disease: a systematic review.","journal-title":"Vaccines (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1177/15579883251391750","key":"coi260011r28","year":"2025","issue":"6","author":"Lipsky","volume":"19","first-page":null,"unstructured":null,"article-title":"HPV prevention in men: a narrative review of strategies, risks, and public health implications.","journal-title":"Am J Mens Health","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-025-92661-x","key":"coi260011r29","year":"2025","issue":"1","author":"Tan","volume":"15","first-page":"8053","unstructured":null,"article-title":"Prevalence and risk factors of high-risk sexual behavior among elderly men with HIV infection in Chongqing, China.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.4103/1947-2714.118931","key":"coi260011r30","year":"2013","issue":"9","author":"Silan","volume":"5","first-page":"515","unstructured":null,"article-title":"HIV risk behavior among men who have sex with men.","journal-title":"N Am J Med Sci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.pvr.2016.02.001","key":"coi260011r31","year":"2016","issue":null,"author":"Choi","volume":"2","first-page":"46","unstructured":null,"article-title":"What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States?","journal-title":"Papillomavirus Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2024.102735","key":"coi260011r34","year":"2024","issue":null,"author":"Prem","volume":"74","first-page":null,"unstructured":null,"article-title":"Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.3389/fpubh.2023.1067299","key":"coi260011r35","year":"2023","issue":null,"author":"Dykens","volume":"11","first-page":null,"unstructured":null,"article-title":"Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally.","journal-title":"Front Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2025.2474891","key":"coi260011r36","year":"2025","issue":"1","author":"Cherif","volume":"21","first-page":null,"unstructured":null,"article-title":"A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.esmorw.2025.100151","key":"coi260011r37","year":"2025","issue":null,"author":"La Rosa","volume":null,"first-page":null,"unstructured":null,"article-title":"Multimodal identification of a rare head and neck cancer patient cohort in the clinical data warehouse of Greater Paris Teaching Hospital.","journal-title":"ESMO Real World Data Digit Oncol","doi-asserted-by":"publisher"},{"DOI":"10.15585/mmwr.mm6908a5","key":"coi260011r39","year":"2020","issue":"8","author":"QuickStats","volume":"69","first-page":"222","unstructured":null,"article-title":"QuickStats: percentage* of children† aged <18 years who received a well-child checkup in the past 12 months,§ by age group and year—National Health Interview Survey, United States, 2008 and 2018¶.","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"publisher"},{"DOI":"10.1080/21645515.2018.1512453","key":"coi260011r40","year":"2019","issue":"1","author":"Hirth","volume":"15","first-page":"146","unstructured":null,"article-title":"Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature.","journal-title":"Hum Vaccin Immunother","doi-asserted-by":"publisher"},{"DOI":"10.15585/mmwr.mm7430a1","key":"coi260011r41","year":"2025","issue":"30","author":"Pingali","volume":"74","first-page":"466","unstructured":null,"article-title":"Vaccination coverage among adolescents aged 13-17 Years—National Immunization Survey-Teen, United States, 2024.","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-04-0551","key":"coi260011r42","year":"2005","issue":"2","author":"Kreimer","volume":"14","first-page":"467","unstructured":null,"article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1186/1758-3284-2-15","key":"coi260011r43","year":"2010","issue":null,"author":"Dayyani","volume":"2","first-page":"15","unstructured":null,"article-title":"Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).","journal-title":"Head Neck Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/GO.23.00464","key":"coi260011r44","year":"2024","issue":null,"author":"Vani","volume":"10","first-page":null,"unstructured":null,"article-title":"Human papillomavirus-attributable head and neck cancers in India-a systematic review and meta-analysis.","journal-title":"JCO Glob Oncol","doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.00370","key":"coi260011r45","year":"2019","issue":"18","author":"Tota","volume":"37","first-page":"1538","unstructured":null,"article-title":"Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals.","journal-title":"J Clin Oncol","doi-asserted-by":"publisher"},{"DOI":null,"key":"coi260011r32","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United States Centers for Disease Prevention and Control? Advisory Committee on Immunization Practices (ACIP). Evidence to recommendations for HPV vaccination harmonization across sexes, ages 22 through 26 years. Published September 5, 2024. Accessed December 26, 2025. https://www.cdc.gov/acip/evidence-to-recommendations/HPV-harmonization-etr.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"coi260011r33","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"United Kingdom Health Security Agency. HPV vaccination guidance for healthcare practitioners. Updated 20 June 2023. Accessed December 26, 2025. https://www.gov.uk/government/publications/hpv-universal-vaccination-guidance-for-health-professionals/hpv-vaccination-guidance-for-healthcare-practitioners","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"coi260011r38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"National Cancer Institute. Surveillance research program, SEER explorer: an interactive website for SEER cancer statistics. Published April 16, 2025. Updated January 8, 2026. Accessed on February 12, 2026. https://seer.cancer.gov/statistics-network/explorer/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Oncology"],"reference-count":45,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,9]]},"references-count":45,"short-container-title":["JAMA Oncol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamaoncol.2026.0496","is_oa":true,"title":"Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males","updated":"2026-04-13T08:15:34+00:00","published_date":"2026-04-09","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/","pmh_id":"oai:pubmedcentral.nih.gov:13067135","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13067135/"}}},"created_at":"2026-05-07T22:49:12.635Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"brand","value":"Gardasil 9","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Anal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Esophageal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Head and Neck Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"HPV-Related Cancers","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"condition","value":"Penile Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"generic","value":"9-valent human papillomavirus vaccine","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"modality","value":"HPV Vaccine","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"sample_size","value":"n=2,905,778 (pre-match); n=1,020,520 (post-match)","value_numeric":2905778},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Brand name 'Gardasil 9' inferred from context (9-valent HPV vaccine); not explicitly stated in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Full text of the article was not accessible; summary is based solely on the abstract and results sections provided.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"Pre-match sample sizes show a marked age difference between vaccinated and unvaccinated groups (mean 13.4 vs. 17.2 years), which propensity score matching attempts to address but residual confounding cannot be excluded.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2026.0496","tag_type":"warning","value":"The specific global database used is not named in the available text, limiting assessment of data quality and generalizability.","value_numeric":null}],"summaries":{"what_studied":"This multicenter retrospective cohort study evaluated whether the 9-valent HPV vaccine reduced incidence of HPV-related cancers (head and neck, esophageal, anal, and penile) in males aged 9–26 years, comparing vaccinated vs. unvaccinated groups over up to 10 years of follow-up (2016–2024) using a large global database.","key_result":"After propensity score matching (n=510,260 per group), vaccinated males had a 46% lower risk of HPV-related cancers vs. unvaccinated males (HR 0.54; 95% CI 0.37–0.81; P=.002). Benefit was consistent in ages 9–14 (HR 0.58; 95% CI 0.34–0.97) and 15–26 (HR 0.50; 95% CI 0.27–0.93).","limitations":"Retrospective design limits causal inference. The database source and completeness of vaccination records are not fully described in the available text. Cancer outcomes in young males are rare, which may introduce instability in subgroup estimates.","practice_takeaway":"These findings support 9-valent HPV vaccination for males across a wide age range (9–26 years), reinforcing sex-neutral vaccination strategies. Clinicians should prioritize HPV vaccination in male adolescents, where early vaccination (ages 9–14) showed meaningful cancer risk reduction."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Anal Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Anal Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Anal Cancer"}}}]]

Papers